# US 2023/0265455 A1 · Improved aav-mediated x-linked retinoschisis therapies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0265455 A1
- Document ID: US20230265455A1
- Status: Published application
- Kind: A1
- Application number: 18/017,726
- Filed: 2021-07-28
- Published: 2023-08-24
- Earliest claimed: 2020-07-29
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Shannon E. Boye; Sanford L. Boye
- Web page: https://patentgrep.com/patent/US20230265455A1

## CPC

- C12N 15/86: Viral vectors
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 48/0058: {Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct}
- A61P 27/02: Ophthalmic agents
- C07K 14/005: from viruses
- C07K 14/47: from mammals
- C07K 14/475: Growth factors; Growth regulators
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N 2830/38: being a stuffer
- C12N 2830/42: being an intron or intervening sequence for splicing and/or stability of RNA
- C12N 2830/48: regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
- C12N 2830/50: regulating RNA stability, not being an intron, e.g. poly A signal
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosure provides for improved recombinant AAV therapies for the treatment of X-linked retinoschisis (XLRS). These therapies are designed for administration to subjects, such as human subjects, including humans diagnosed with or suffering from XLRS.

## Claims

### Claim 1

An adeno-associated virus (AAV) vector comprising a polynucleotide that comprises (i) a heterologous nucleic acid encoding a retinoschisin protein, and (ii) an intron, splice donor region, splice acceptor region, or any combination of two or more thereof.

### Claim 2 (depends on 1)

The AAV vector of claim 1, comprising the intron, wherein the intron comprises a splice donor region and/or a splice acceptor region.

### Claim 3 (depends on 1, 2)

The AAV vector of claim 1 or 2, comprising the intron, wherein the intron comprises a sequence having at least at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleic acid sequence of SEQ ID NO: 20 or 21.

### Claim 4 (depends on 3)

The AAV vector of claim 3, wherein the intron comprises the nucleic acid sequence of SEQ ID NO: 20 or 21.

### Claim 5 (depends on 1, 2, 3, 4)

The AAV vector of any one of claims 1-4, comprising the intron, wherein the intron comprises an SV40 intron.

### Claim 6 (depends on 1, 2, 3, 4, 5)

The AAV vector of any one of claims 1-5, comprising a post-transcription regulatory element.

### Claim 7

An AAV vector comprising a polynucleotide that comprises (i) a heterologous nucleic acid encoding a retinoschisin protein and (ii) a post-transcription regulatory element.

### Claim 8 (depends on 6, 7)

The AAV vector of claim 6 or claim 7, wherein the post-transcription regulatory element comprises a woodchuck hepatitis virus post-transcription regulatory element (WPRE).

### Claim 9 (depends on 6, 7, 8)

The rAAV vector of any one of claims 6-8, wherein the post-transcription regulatory element comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15.

### Claim 10 (depends on 6, 7, 8, 9)

The rAAV vector of any one of claims 6-9, wherein the post-transcription regulatory element is positioned 3′ of the heterologous nucleic acid.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The AAV vector of any one of claims 1-10, wherein the retinoschisin protein is a human retinoschisin protein.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The AAV vector of any one of claims 1-11, wherein the heterologous nucleic acid does not comprise the 5′ untranslated region of human retinoschisin.

### Claim 13 (depends on 12)

The AAV vector of claim 12, wherein the 5′ untranslated region comprises the nucleic acid sequence of SEQ ID NO: 39.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The AAV vector of any one of claims 1-13, wherein the nucleic acid does not comprise the 3′ untranslated region of human retinoschisin.

### Claim 15 (depends on 14)

The AAV vector of claim 14, wherein the 3′ untranslated region comprises the nucleic acid sequence of SEQ ID NO: 40.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The AAV vector of any one of claims 1-15, wherein the heterologous nucleic acid comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleotide sequence of SEQ ID NO: 8.

### Claim 17

A recombinant AAV (rAAV) vector comprising a polynucleotide that comprises a heterologous nucleic acid comprising a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the nucleotide sequence of SEQ ID NO: 8.

### Claim 18 (depends on 17)

The rAAV vector of claim 17, wherein the polynucleotide comprises a post-transcription regulatory element.

### Claim 19 (depends on 18)

The rAAV vector of claim 18, wherein the post-transcription regulatory element comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 15.

### Claim 20 (depends on 18, 19)

The rAAV vector of claim 18 or 19, wherein the post-transcription regulatory element is positioned 3′ of the heterologous nucleic acid.

### Claim 21 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The rAAV vector of any one of claims 1-20, wherein the heterologous nucleic acid comprises a sequence that differs by 5, 10, 15, 20, 25, or more than 25 nucleotides from the nucleotide sequence of SEQ ID NO: 8.

### Claim 22 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21)

The rAAV vector of any one of claims 1-21, wherein the heterologous nucleic acid comprises the sequence set forth as SEQ ID NO: 8.

### Claim 23 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22)

The rAAV vector of any one of claims 1-22, wherein the heterologous nucleic acid comprises the sequence set forth as SEQ ID NO: 9.

### Claim 24 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23)

The rAAV vector of any one of claims 1-23, wherein the polynucleotide comprises the sequence of SEQ ID NO: 10.

### Claim 25 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24)

The rAAV vector of any one of claims 1-24, wherein the heterologous nucleic acid is operably linked to one or more regulatory elements that direct expression of the heterologous nucleic acid in a photoreceptor cell or retinal pigment epithelium cell.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

The rAAV vector of any one of claims 1-25, wherein the polynucleotide comprises a promoter that is capable of expressing the nucleic acid sequence in one or more photoreceptors or retinal pigment epithelial cells of a mammalian eye.

### Claim 27 (depends on 26)

The rAAV vector of claim 26, wherein the promoter is selected from a rhodopsin kinase promoter, a rhodopsin promoter, an IRBP promoter, a chimeric human Retinoschisin-IRBP enhancer (RS/IRPB); a red/green cone opsin promoter, a Cone Arrestin promoter, a chimeric IRBP enhancer-cone transducin promoter, a chicken beta actin promoter, and a truncated chimeric chicken beta actin (smCBA) promoter.

### Claim 28 (depends on 26, 27)

The rAAV vector of claim 26 or 27, wherein the promoter is a human rhodopsin kinase (hGRK1) promoter.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The rAAV vector of any one of claims 1-28, wherein the vector is self-complementary.

### Claim 30 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The rAAV vector of any one of claims 1-29, wherein the polynucleotide is flanked by one or more inverted terminal repeat (ITR) sequences.

### Claim 31 (depends on 30)

The AAV vector of claim 30, wherein the one or more ITR sequences comprises a nucleic acid sequence having at least 80%, 85%, 90%, 92%, 95%, 98%, or 99% identity to SEQ ID NOs: 22-25.

### Claim 32 (depends on 30, 31)

The AAV vector of claim 30 or 31, wherein the one or more ITR sequences comprises the nucleic acid sequence of SEQ ID NOs: 22-25.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)

The AAV vector of any one of claims 1-32 further comprising a polyadenylation signal.

### Claim 34 (depends on 33)

The AAV vector of claim 33, wherein the polyadenylation signal comprises a bovine growth factor polyadenylation signal.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34)

The rAAV vector of any one of claims 1-34, wherein the vector comprises a nucleotide sequence having at least 95%, 98%, or 99% identity to the nucleotide sequence of any one of SEQ ID NOs: 16, 17, and 31-35.

### Claim 36 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35)

The rAAV vector of any one of claims 1-35, wherein the vector comprises the nucleotide sequence of any one of SEQ ID NOs: 16, 17, and 31-35.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A recombinant adeno-associated viral (rAAV) particle comprising a capsid, wherein the rAAV particle further comprises the rAAV vector of any one of claims 1-36.

### Claim 38 (depends on 37)

The rAAV particle of claim 37, wherein the capsid comprises an AAV44.9(E531D) capsid.

### Claim 39 (depends on 37)

The rAAV particle of claim 37, wherein the capsid comprises a protein that comprises the amino acid sequence of any one of SEQ ID NOs: 1-6, 18, and 36-38.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36)

A recombinant adeno-associated viral (rAAV) particle comprising an AAV44.9(E531D) capsid and the rAAV vector of any one of claims 1-36.

### Claim 41 (depends on 37)

The rAAV particle of claim 37, wherein the capsid comprises any of the following capsid proteins: AAV44.9(T492V+E531D), AAV44.9(Y446F+E531D), and AAV44.9(Y446F+T492V+E531D).

### Claim 42 (depends on 37)

The rAAV particle of claim 37, wherein the capsid comprises any of the following capsid proteins: AAVS and variants thereof, AAV7 and variants thereof, AAV8 and variants thereof, AAV9 and variants thereof, AAV2(4pMut)ΔHS, AAV44.9, AAV8(Y447F+Y733F+T494V), AAVrh.8, AAVrh.8R, AAVrh.10, AAVrh.74, AAV2TT, AAV2HBKO, and AAVAnc80.

### Claim 43 (depends on 37)

The rAAV particle of claim 37, wherein the capsid comprises an AAV5 capsid protein, or a variant thereof.

### Claim 44 (depends on 37)

The rAAV particle of claim 37, wherein the capsid protein comprises AAV44.9(Y446F+T492V+E531D).

### Claim 45 (depends on 37, 38, 39, 40, 41, 42, 43, 44)

A composition comprising a plurality of the rAAV particle of any one of claims 37-44 further comprising one or more pharmaceutically acceptable carriers, buffers, diluents or excipients.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

A cell comprising the rAAV vector of any one of claims 1-36 or the rAAV particle of any one of claims 37-44.

### Claim 47 (depends on 46)

The cell of claim 46, wherein the cell is a mammalian cell.

### Claim 48 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for transducing a mammalian photoreceptor cell or retinal pigment epithelium cell, the method comprising administering to one or both eyes of a mammal the rAAV particle of any one of claims 37-44 or the composition of claim 45.

### Claim 49 (depends on 37, 38, 39, 40, 41, 42, 43, 44, 45)

A method for treating or ameliorating X-linked retinoschisis (XLRS) in a mammal, the method comprising subretinally administering to one or both eyes of the mammal the rAAV particle of any one of claims 37-44 or the composition of claim 45 in an amount sufficient to treat or ameliorate the one or more symptoms of the retinoschisis in the mammal.

### Claim 50 (depends on 49)

The method of claim 49, wherein the mammal is human.

### Claim 51 (depends on 48, 49, 50)

The method of any one of claims 48-50, wherein the particle is administered in an amount of between 5×1010 and 1×1012 vector genomes (vgs)/mL.

### Claim 52 (depends on 48, 49, 50, 51)

The method of any one of claims 48-51, wherein step of administering a) preserves one or more photoreceptor cells, b) restores laminar retinal structure, c) restores one or more rod- and/or cone-mediated functions, d) restores completely or partially visual behavior in one or both eyes, or e) any combination thereof.

### Claim 53 (depends on 48, 49, 50, 51, 52)

The method of any one of claims 48-52, wherein the step of administering restores laminar retinal structure.

### Claim 54 (depends on 48, 49, 50, 51, 52, 53)

The method of any one of claims 48-53, wherein the step of administering comprises subretinal administration to a fovea of one or both eyes of the mammal.

### Claim 55 (depends on 54)

The method of claim 54, wherein detachment of the fovea is minimized.
